Synthesis and antibacterial evaluation of novel 8-fluoro Norfloxacin derivatives as potential probes for methicillin and vancomycin-resistant Staphylococcus aureus

European Journal of Medicinal Chemistry

Volumn 46, Issue 4, 2011, Pages 1232-1244

  Sunduru, Naresh ^a   Gupta, Leena ^a   Chauhan, Kuldeep ^a   Mishra, Nripendra N ^a   Shukla, Praveen K ^a   Chauhan, Prem M S ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

1,3,5 triazine; Fluoroquinolone; K. pneumoniae; MRSA; Norfloxacin; Pyrimidine; VRSA

Indexed keywords

1 ETHYL 6,8 DIFLUORO 4 OXO 7 (4 PHENYLPIPERAZIN 1 YL) 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6,8 DIFLUORO 4 OXO 7 (PIPERAZIN 1 YL) 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6,8 DIFLUORO 4 OXO 7 (PIPERIDIN 1 YL) 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6,8 DIFLUORO 4 OXO 7 (PROPYLAMINO) 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6,8 DIFLUORO 7 (2 MORPHOLINOETHYLAMINO) 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6,8 DIFLUORO 7 (3 MORPHOLINOPROPYLAMINO) 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6,8 DIFLUORO 7 (4 METHYLPIPERAZIN 1 YL) 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6,8 DIFLUORO 7 (ISOPROPYLAMINO) 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6,8 DIFLUORO 7 MORPHOLINO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 7 (4 ETHYLPIPERAZIN 1 YL) 6,8 DIFLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 6,8 DIFLUORO 4 OXO 7 (4 PHENYLPIPERAZIN 1 YL) 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 6,8 DIFLUORO 4 OXO 7 (PIPERAZIN 1 YL) 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 6,8 DIFLUORO 4 OXO 7 (PIPERIDIN 1 YL) 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 6,8 DIFLUORO 4 OXO 7 (PROPYLAMINO) 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 6,8 DIFLUORO 7 (4 METHYLPIPERAZIN 1 YL) 4 OXO 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 6,8 DIFLUORO 7 (ISOPROPYLAMINO) 4 OXO 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 6,8 DIFLUORO 7 MORPHOLINO 4 OXO 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 (4 BENZYLPIPERAZIN 1 YL) 1 ETHYL 6,8 DIFLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 (4 BENZYLPIPERAZIN 1 YL) 6,8 DIFLUORO 4 OXO 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 (4 ETHYLPIPERAZIN 1 YL) 6,8 DIFLUORO 4 OXO 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 (BUTYLAMINO) 1 ETHYL 6,8 DIFLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 (BUTYLAMINO) 6,8 DIFLUORO 4 OXO 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 (TERT BUTYLAMINO) 1 ETHYL 6,8 DIFLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 (TERT BUTYLAMINO) 6,8 DIFLUORO 4 OXO 1 [4 (TRIFLUOROMETHYL)BENZYL] 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 8 FLUORONORFLOXACIN DERIVATIVE; CIPROFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; FLUORENES; FLUOROBENZENES; FOLIC ACID ANTAGONISTS; KLEBSIELLA PNEUMONIAE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; NORFLOXACIN; TETRAHYDROFOLATE DEHYDROGENASE; VANCOMYCIN RESISTANCE;

EID: 79952281076     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.01.044     Document Type: Article

References (38)

1. H. Koga, A. Itoh, S. Murayama, S. Suzue, and T. Irikura J. Med. Chem. 23 1980 1358 1363
2. R. Wise, J.M. Andrews, and L.J. Edwards Antimicrob. Agents Chemother. 23 1983 559 564
3. K. Grohe, and H. Heitzer Liebigs Ann. Chem. 1987 29 37
4. J.J. Schentag Clin. Ther. 22 2000 372 387
5. T.D. Gootz, K.E. Brighty, M.R. Anderson, S.L. Haskell, J.A. Sutcliffe, M.J. Castaldi, Miller, S.A, Presented at the 32th Meeting of the ICAAC, Anaheim, CA, 1992; Abstract 751.
6. N. Harnett, S. Brown, and C. Krishnan Antimicrob. Agents Chemother. 35 1991 1911 1913
7. L.J.V. Piddock Drugs 58 1999 11 18
8. P.C. Appelbaum, and P.A. Hunter Int. J. Antimicrob. Agents 16 2000 5 15
9. R. Canton, T.M. Coque, and F. Baquero Curr. Opin. Infect. Dis. 16 2003 315 325
10. D.L. Stevens Curr. Opin. Infect. Dis. 16 2003 189 191
11. S.B. Levy, and B. Marshall Nat. Med. 12 2004 S122 S129
12. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004 Am. J. Infect. Control 32 2004 470 485
13. D. Styers, D.J. Sheehan, P. Hogan, and D.F. Sahm Ann. Clin. Microbiol. Antimicrob. 5 2006 2
14. E.M. Graffunder, and R.A. Venezia J. Antimicrob. Chemother. 49 2002 999 1005
15. A. Asensio, A. Guerrero, C. Quereda, M. Lizan, and M. Martinez-Ferrer Infect. Control Hosp. Epidemiol. 17 1996 20 28
16. D.L. Monnet Infect. Control Hosp. Epidemiol. 19 1998 552 559
17. P.C. Appelbaum Clin. Microbiol. Infect. 12 2006 16 23
18. K. Hiramatsu, L. Cui, and K. Kuwahara-Arai Lancet 364 2004 565 566
19. S. Chang, D.M. Sievert, J.C. Hageman, M.L. Boulton, F.C. Tenover, F.P. Shah, S. Downes, J.T. Rudrik, G.R. Pupp, W.J. Brown, D. Cardo, and S.K.N. Fridkin N. Engl. J. Med. 348 2003 1342 1347
20. F.C. Tenover, L.M. Weigel, P.C. Appelbaum, L.K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C.M. O'Hara, L. Jevitt, J.B. Patel, and B. Bozdogan Antimicrob. Agents Chemother. 48 2004 275 280
21. J.Z. Montgomerie Rev. Infect. Dis. 1 1979 736 753
22. C.A.J. Hart J. Hosp. Infect. 23 1993 83 86
23. C. Pena, M. Pujol, C. Ardanuy, A. Ricart, R. Pallares, J. Linares, J. Ariza, and F. Gudiol Antimicrob. Agents Chemother. 42 1998 53 58
24. M. Cartelle, M. del Mar Tomas, S. Pertega, A. Beceiro, M.A. Dominguez, D. Velasco, F. Molina, R. Villanueva, and G.J. Bou J. Clin. Microbiol. 42 2004 4242 4249
25. C.J.R. Willmott, S.E. Critchlow, I.C. Eperon, and A. Maxwell J. Mol. Biol. 242 1994 351 363
26. T.D. Gootz, J.F. Barrett, and J.A. Sutcliffe Antimicrob. Agents Chemother. 34 1990 8 12
27. G.H. Hitchings, and J.J. Burchall Adv. Enzymol. Relat. Areas Mol. Biol. 27 1965 417 468
28. S. Hawser, S. Lociuro, and K. Islam Biochem. Pharmacol. 71 2006 941 948
29. P. Schneider, S. Hawser, and K. Islam Bioorg. Med. Chem. Lett. 13 2003 4217 4221
30. S.R.M. Bushby, and G.H. Hitchings Br. J. Pharmacol. Chemother. 33 1968 72 90
31. M. Adra, and K.R. Lawrence Ann. Pharmacother. 38 2004 338 341
32. S.A. Grim, R.P. Rapp, C.A. Martin, and M.E. Evans Pharmacotherapy 25 2005 253 264
33. N. Markowitz, E.L. Quinn, and L.D. Saravolatz Ann. Intern. Med. 117 1992 390 398
34. J. Turnidge, and M.L. Grayson Drugs 45 1993 353 366
35. S. Leyva, and E. Leyva Tetrahedron 63 2007 2093 2097
36. W. Zhang Org. Lett. 5 2003 1011 1013
37. N. Yamamoto, J. Fujita, T. Shinzato, F. Higa, M. Tateyama, M. Tohyama, I. Nakasone, and N. Yamane Int. J. Antimicrob. Agents 27 2006 171 173
38. National Committee for Clinical Laboratory Standards Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard fifth ed. 2000 NCCLS Villanova, PA pp. M7-A5